TSX : CTX.TO

Crescita Therapeutics Inc.

$0.79 CAD

$0 (0.0%)

Volume
1K
Average Volume
23.16K
Market Capitalization
$14.71M
P/E Ratio
-43.17
Dividend Yield
0.00%
Price Target
Year High
$0.79
Year Low
$0.40
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.80
Company Overview

TSX

Serge Verreault

Drug Manufacturers - Specialty & Generic

Healthcare

CTX.TO

71

CA

CAD

https://www.crescitatherapeutics.com

14506804722

225847102

N/A

Liquidity Metrics

0.17

2.80

2.06

1.55

0.00

Sales & Valuation

$21.12M

0.63

1.02

6.63

0.12

Profitability

-$0.0049

-$92000

-1.38%

-1.34%

-2.07%

-1.44%

P/E Metrics

-43.17

-1.78

-1.78

Analyst Price Target & Rating

N/A

0/5

0 Analysts

%

Financial Health Scores

-0.20

5/9

$10.17M

$22.18M

$7.76M

$62000

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Jose DaRocha Chief Financial Officer
Serge Verreault President, Chief Executive Officer & Director
Linda Kisa Vice-President of Reporting, Corporate Affairs & Secretary
Poll Results

No votes yet today — be the first to share your view!

About Crescita Therapeutics Inc. (TSX:CTX.TO) Stock

Crescita Therapeutics Inc. is a dermatology-focused enterprise that offers a comprehensive portfolio of both over-the-counter skincare products and prescription medications, distributed across Canada, the United States, and other international markets. The company operates through three principal divisions: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. Central to its innovation are proprietary platform technologies, MMPE and DuraPeel, which are specifically employed in the formulation of topical treatments containing cannabis and hemp compounds. Crescita's prescription drug lineup includes Pliaglis, a topical local anesthetic cream designed to provide dermal analgesia on intact skin prior to superficial dermatological procedures. Its development pipeline fea ... tures CTX-101, a Phase III topical corticosteroid formulation utilizing MMPE technology for treating plaque psoriasis, and CTX-102, a Phase I topical therapy leveraging MMPE for an unspecified skin condition. Furthermore, several pre-clinical dermatology products are in development, also based on MMPE technology, for various prescription skin disease treatments. In the non-prescription sector, Crescita offers a broad selection of skincare items. Under the Laboratoire Dr Renaud brand, it provides facial creams, cleansers, exfoliants, masks, serums, and suncare products aimed at addressing concerns such as aging, acne, rosacea, pigmentation, dehydration, and sensitivity. The Pro-Derm line consists of dermocosmetic solutions specifically formulated for anti-aging medical procedures, while the Alyria brand targets a diverse range of skincare issues. Products under the Dermazulene brand are primarily intended for Asian consumers. The company also markets NCTF 135 HA, a skin revitalization solution focused on improving skin quality and reducing fine lines. Crescita has established key collaborations, including a development and licensing agreement with Sundial Growers Inc. for cannabis product development, a commercialization license agreement with Cantabria Labs Inc., and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was founded in 2016 and maintains its corporate headquarters in Laval, Canada.

Frequently Asked Questions

What is the current Crescita Therapeutics Inc. (CTX.TO) stock price?

Crescita Therapeutics Inc.(TSX:CTX.TO) stock price is $0.79 in the last trading session. During the trading session, CTX.TO stock reached the peak price of $0.79 while $0.4 was the lowest point it dropped to. The percentage change in CTX.TO stock occurred in the recent session was 0.0% while the dollar amount for the price change in CTX.TO stock was $0.

CTX.TO's industry and sector of operation?

The TSX listed CTX.TO is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of CTX.TO?

Jose DaRocha | Chief Financial Officer
Serge Verreault | President, Chief Executive Officer & Director
Linda Kisa | Vice-President of Reporting, Corporate Affairs & Secretary
|
|

How many employees does CTX.TO have?

Number of CTX.TO employees currently stands at 71. CTX.TO operates from 2805 Place Louis-R Renaud, Laval, QC H7V 0A3, CA.

Link for CTX.TO official website?

Official Website of CTX.TO is: https://www.crescitatherapeutics.com

How do I contact CTX.TO?

CTX.TO could be contacted at phone #14506804722 and can also be accessed through its website. CTX.TO operates from 2805 Place Louis-R Renaud, Laval, QC H7V 0A3, CA.

How many shares of CTX.TO are traded daily?

The average number of CTX.TO shares traded daily for last 3 months was 23.16K.

What is the market cap of CTX.TO currently?

The market value of CTX.TO currently stands at $14.71M with its latest stock price at $0.79